Clinical trial
Phase 1, Open-label, Two Routes IV and Intra-hepatic Artery Dose-escalation Clinical Study to Evaluate the Safety and Efficacy of ET1402L1-CAR T- Cells in AFP Expressing Hepatocellular Carcinoma (HCC)
NCT03349255 is registered in ClinicalTrials.gov with Aeon Therapeutics (Shanghai) Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1, Open-label, Two Routes IV and Intra-hepatic Artery Dose-escalation Clinical Study to Evaluate the Safety and Efficacy of ET1402L1-CAR T- Cells in AFP Expressing Hepatocellular Carcinoma (HCC)
- Lead sponsor
- Aeon Therapeutics (Shanghai) Co., Ltd.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- October 6, 2017
- Completion date
- January 10, 2019
- Enrollment
- 3 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hepatocellular carcinoma, liver cancer, liver neoplasms, metastatic liver cancer